FDA warns companies marketing unproven products, derived from marijuana, that claim to treat or cure cancer
FDA Press Announcements Nov 05, 2017
As part of the U.S. Food and Drug AdministrationÂs ongoing efforts to protect consumers from health fraud, the agency issued warning letters to four companies illegally selling products online that claim to prevent, diagnose, treat, or cure cancer without evidence to support these outcomes. Selling these unapproved products with unsubstantiated therapeutic claims is not only a violation of the Federal Food, Drug and Cosmetic Act, but also can put patients at risk as these products have not been proven to be safe or effective. The deceptive marketing of unproven treatments may keep some patients from accessing appropriate, recognized therapies to treat serious and even fatal diseases.
The FDA has grown increasingly concerned at the proliferation of products claiming to treat or cure serious diseases like cancer. In this case, the illegally sold products allegedly contain cannabidiol (CBD), a component of the marijuana plant that is not FDA approved in any drug product for any indication. CBD is marketed in a variety of product types, such as oil drops, capsules, syrups, teas, and topical lotions and creams. The companies receiving warning letters distributed the products with unsubstantiated claims regarding preventing, reversing or curing cancer; killing/inhibiting cancer cells or tumors; or other similar anti-cancer claims. Some of the products were also marketed as an alternative or additional treatment for AlzheimerÂs and other serious diseases.
ÂSubstances that contain components of marijuana will be treated like any other products that make unproven claims to shrink cancer tumors. We donÂt let companies market products that deliberately prey on sick people with baseless claims that their substance can shrink or cure cancer and weÂre not going to look the other way on enforcing these principles when it comes to marijuana-containing products, said FDA Commissioner Scott Gottlieb, MD. ÂThere are a growing number of effective therapies for many cancers. When people are allowed to illegally market agents that deliver no established benefit they may steer patients away from products that have proven, anti-tumor effects that could extend lives.Â
The FDA issued warning letters to four companiesÂGreenroads Health, Natural Alchemist, ThatÂs Natural! Marketing and Consulting, and Stanley Brothers Social Enterprises LLCÂciting unsubstantiated claims related to more than 25 different products spanning multiple product webpages, online stores and social media websites. The companies used these online platforms to make unfounded claims about their products' ability to limit, treat or cure cancer and other serious diseases. Examples of claims made by these companies include:
ÂWe have an obligation to provide caregivers and patients with the confidence that drugs making cancer treatment claims have been carefully evaluated for safety, efficacy, and quality, and are monitored by the FDA once theyÂre on the market, Commissioner Gottlieb added. ÂWe recognize that thereÂs interest in developing
Go to Original
The FDA has grown increasingly concerned at the proliferation of products claiming to treat or cure serious diseases like cancer. In this case, the illegally sold products allegedly contain cannabidiol (CBD), a component of the marijuana plant that is not FDA approved in any drug product for any indication. CBD is marketed in a variety of product types, such as oil drops, capsules, syrups, teas, and topical lotions and creams. The companies receiving warning letters distributed the products with unsubstantiated claims regarding preventing, reversing or curing cancer; killing/inhibiting cancer cells or tumors; or other similar anti-cancer claims. Some of the products were also marketed as an alternative or additional treatment for AlzheimerÂs and other serious diseases.
ÂSubstances that contain components of marijuana will be treated like any other products that make unproven claims to shrink cancer tumors. We donÂt let companies market products that deliberately prey on sick people with baseless claims that their substance can shrink or cure cancer and weÂre not going to look the other way on enforcing these principles when it comes to marijuana-containing products, said FDA Commissioner Scott Gottlieb, MD. ÂThere are a growing number of effective therapies for many cancers. When people are allowed to illegally market agents that deliver no established benefit they may steer patients away from products that have proven, anti-tumor effects that could extend lives.Â
The FDA issued warning letters to four companiesÂGreenroads Health, Natural Alchemist, ThatÂs Natural! Marketing and Consulting, and Stanley Brothers Social Enterprises LLCÂciting unsubstantiated claims related to more than 25 different products spanning multiple product webpages, online stores and social media websites. The companies used these online platforms to make unfounded claims about their products' ability to limit, treat or cure cancer and other serious diseases. Examples of claims made by these companies include:
- ÂCombats cancer cells;Â
- ÂCBD makes cancer cells commit Âsuicide without killing other cells;Â
- ÂCBD has anti-proliferative properties that inhibit cell division and growth in certain types of cancer, not allowing the tumor to grow;Â and
- ÂNon-psychoactive cannabinoids like CBD may be effective in treating cancer tumors.Â
ÂWe have an obligation to provide caregivers and patients with the confidence that drugs making cancer treatment claims have been carefully evaluated for safety, efficacy, and quality, and are monitored by the FDA once theyÂre on the market, Commissioner Gottlieb added. ÂWe recognize that thereÂs interest in developing
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries